Bioluminescence Ventures is a biotechnology venture firm investing in Drug Discovery Platforms (Oncology, Immunology, Neuroscience, Genetic Diseases), Applied Biology Platforms, and Computational Biology Platforms. The firm has AUM of $550M+ with offices in San Francisco and Cambridge (MA). Biomedical research is entering a Golden Age of Discovery – industrialized by HW/SW technologies, powered by longitudinal multi-modal data sets, and translated into novel therapies / therapeutic modalities by a new generation of multidisciplinary scientific founders. Bioluminescence was conceptualized and launched to potentiate this next generation of translational founders. Patient impact is our guiding light, and we see this light radiating from exceptional translational founders. Our growing team of multidisciplinary biotechnology researcher-operator-investors seek to earn trust through a shared understanding of the science and a shared vision for its potential to address unmet clinical needs. We seek to provide technical support as they translate and develop their science. We seek to provide financing support through the long and arduous journey. We also seek to provide business advisory and development support as the science matures toward co-development and co-commercialization partnerships. By obsessively and comprehensively meeting the needs of our founders, we aim to maximize their downstream impact on patients. We aim to make their light shine brighter. For more information, please visit Bioluminescence.com.